Quotient's ALBAcyte Reagent Red Blood Cell products receive U.S. FDA license

Quotient Biodiagnostics, Inc. (Quotient), a supplier of innovative and high-quality transfusion diagnostic products to hospitals, blood banks and other healthcare institutions, is pleased to announce that its range of ALBAcyte® Reagent Red Blood Cell products have been licensed for sale in the USA by the Food and Drug Administration (FDA).

"Licensing of the ALBAcyte® Reagent Red Blood Cell products by the FDA satisfies a crucial stage in the development of Quotient's strategy to address the important US market with a full range of transfusion diagnostic products. It significantly increases the breadth of ABO testing, antibody screening and antibody identification products Quotient can now offer its key US client base" said Jeremy Stackawitz, President and CEO of Quotient.

Reagent red blood cells are used extensively for ABO testing, antibody screening and antibody identification. Quotient's new reagent red blood cells include reverse cells, screening cells and both untreated and enzyme-treated identification panels and will join Quotient's IgG Sensitized Red Blood Cells already on the market. All Quotient reagent red blood cell products will be sold under the ALBAcyte® brand name, and will be available for use or evaluation by the end of February 2012.

"Since entering the US market with our range of ABO Rh and rare antisera, we have been welcomed by the blood banking community who have appreciated our innovative, high-quality and cost-effective products. We are very excited to extend these same values to the seven new reagent red blood cell products now being launched and to additional products to be launched as we build our product offering further in the USA. Combined with our existing products on sale in the USA, these new products will allow Quotient to better serve its existing and future customers," said Michael Hannan, E.V.P., Commercial Operations for Quotient.

Source: Quotient Biodiagnostics